Yahoo Finance

Wolfe Research initiated coverage of Stevanato Group (STVN) with an Outperform rating and $28 price target The company is poised to return to double-digit revenue growth as a supplier of key enabling components and solutions to biopharma, the analyst tells investors in a research note. The firm does not expect Stevanato’s growth to inflect, but believes it “is on the verge of turning the corner.” The company’s revenue growth should return to high-single digit levels over the course of 2025 and margins will improve via growth and mix, contends Wolfe.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on STVN:

• Stevanato Group initiated with an Outperform at Wolfe Research

• Stevanato Group assumed with an Equal Weight at Morgan Stanley

• Stevanato Group Sees Revenue Rise Amid Engineering Challenges

• Stevanato Group price target raised to $24 from $23 at UBS

• Stevanato Group Q3 2024 Earnings Overview